Johnson & Johnson in Advanced Talks to Buy Ollin Biosciences
The proposed deal could reach $3.4 billion, including cash and payments tied to milestones for Ollin’s experimental eye drug.
Makkler Newsroom · Nov 16, 08:36 AM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $283.67 (+0.4%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.